PIERRE FABRE SINGAPORE PTE. LTD.

概览

试验阶段分布

暂无试验阶段数据

试验状态分布

暂无试验数据

药物批准

按机构分类的批准

HSA

Health Sciences Authority

6

药物批准

近期批准

MEKTOVI FILM-COATED TABLET 15MG

HSA

4.1. THERAPEUTIC INDICATIONS Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by a validated test.

2023-07-19

BRAFTOVI HARD CAPSULE 75MG

HSA

4.1. THERAPEUTIC INDICATIONS Melanoma Encorafenib, in combination with binimetinib, is indicated for the treatment of adult patients who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by a validated test. Colorectal Cancer Encorafenib, in combination with cetuximab, is indicated for the treatment of adult patients who have metastatic colorectal cancer (mCRC) with a BRAF V600E mutation as detected by a validated test, and who have received prior systemic therapy.

2023-07-19

BRAFTOVI HARD CAPSULE 50MG

HSA

4.1. THERAPEUTIC INDICATIONS Melanoma Encorafenib, in combination with binimetinib, is indicated for the treatment of adult patients who have unresectable or metastatic melanoma with a BRAF V600E or V600K mutation, as detected by a validated test. Colorectal Cancer Encorafenib, in combination with cetuximab, is indicated for the treatment of adult patients who have metastatic colorectal cancer (mCRC) with a BRAF V600E mutation as detected by a validated test, and who have received prior systemic therapy.

2023-07-19

NAVELBINE SOFT CAPSULE 20 MG

HSA

4.1 – Therapeutic indications Non-small cell lung cancer – Advanced Breast Cancer

2004-05-22

NAVELBINE SOFT CAPSULE 30 MG

HSA

4.1 – Therapeutic indications Non-small cell lung cancer – Advanced Breast Cancer

2004-05-22

NAVELBINE INJECTION 10 mg/ml

HSA

**INDICATIONS** - Non-small cell lung cancer - Metastatic breast cancer